AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06213506 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY
Description: -1 dose of MenACWY vaccine administered intramuscularly at Day 1 to adults in the Adults_Control group; -2 doses of MenACWY vaccine administered intramuscularly at Day 1 and Day 57 to children in the Children_Control B and Children_Control C groups, and at Day 1 and Day 85 to infants in the Infants_9M_Control A, Infants_9M_Control B and Infants_9M_Control C groups; -3 doses of MenACWY vaccine administered intramuscularly at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase) to infants in the Infants_6W_Control A, Infants_6W_Control B, Infants_6W_Control C and Infants_6W_Control_2 groups. A 4th dose of MenACWY vaccine is administered after the trial ends, to infants in the aforementioned study groups, as per the licensed indication and in private vaccination settings.
Study NCT06213506 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: DTPa-HBV-IPV+Hib
Description: 1 dose of DTPa-HBV-IPV+Hib vaccine administered intramuscularly at Day 169 to infants in the Infants_9M_Control A, Infants_9M_Control B and Infants_9M_Control C groups.
Study NCT06213506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 1 dose of Placebo administered intramuscularly at Day 57 to adults in the Adults_Control group.
Study NCT05497128 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrahigh-speed cut rate 27-gauge system
Description: The ultrahigh-speed cut rate 27-gauge system (27+®GA HYPERVIT® Vitrectomy Probe (Alcon Laboratories, Fort Worth, TX, USA))
Study NCT05497128 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard cut rate 27-gauge system
Description: The current standard cut rate 27-gauge vitrectomy system (27+®GA Advanced ULTRAVIT® Vitrectomy Probe (Alcon Laboratories, Fort Worth, TX, USA))
Study NCT05414760 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Womed Leaf
Description: Womed Leaf™ is a sterile, degradable film of poly(D,L-lactide) (PLA) and poly(ethylene oxide) (PEO). PEO is a biocompatible polymer with anti-adhesion and swelling properties. It is polymerized with hydrophobic PLA to form a degradable film. Womed Leaf™ is inserted in the uterine cavity by a gynaecologist surgeon with a 5 mm diameter flexible inserter. Once released, the film unfolds and grows into the uterine cavity to create a mechanical barrier and keep the uterine walls separated for approximately one week. It is then degraded and discharged naturally through the cervix.
Study NCT06189274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anatomy-Based Electrode Array Selection
Description: Use of pre-operative imaging to select the appropriate length electrode vs standard of care
Study NCT06189274 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Electrode Array Selection
Description: Use of standard of care electrode which is the FLEX 28 electrode
Study NCT06197529 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Homeostatic Plasticity
Description: Anodal tDCS S1/M1
Study NCT06197529 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Homeostatic Plasticity
Description: Anodal tDCS S1/M1
Study NCT06197529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Homeostatic Plasticity
Description: Anodal tDCS S1/M1
Study NCT06197529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical alone (Capsaicin 8% Patch)
Description: 4x4 patch
Study NCT06197529 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Patch
Description: 4x4 patch
Study NCT06197529 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: 4x4 patch
Study NCT06197529 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo Patch
Description: 4x4 patch
Study NCT06197529 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Homeostatic Plasticity (Sham)
Description: sham Homeostatic Plasticity protocol over S1
Study NCT05624541 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measurements
Description: All infants at high risk of cp will be assessed by Specific Test of Early Infant Motor Performance (STEP) Version 3.0 at term age and at corrected age 3 months, by Hammersmith Infant Neurological Examination (HINE) a corrected age 3 and 6 months, also BAYLEY-III Infant and Toddler Development Assessment Scale (BAYLEY-III) at corrected 6 months.
Study NCT06325501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol 200mcg Tab
Description: receiving a preoperative rectal dose of 800 ug of misoprostol half an hour before surgery
Study NCT06325501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: after the induction of general anaesthesia (GA), an infusion of 40 IU oxytocin in 500 ml normal saline was started at the rate of 250 ml/hour
Study NCT06538766 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength training with an internal focus of attention
Description: A 4 weeks strength training program of seated calf raises with progressive overload is carried out. A supervisor applies force specific internal focus instruction in three sessions per week with at least 48h rest time. One session consists of 3 series until failure with 75%RM. Rest intervals between series are defined as 2 minutes.
Study NCT06538766 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training with a proprioceptive external focus of attention
Description: A 4 weeks strength training program of seated calf raises with progressive overload is carried out. A supervisor applies force specific proprioceptive external focus instruction in three sessions per week with at least 48h rest time. One session consists of 3 series until failure with 75%RM. Rest intervals between series are defined as 2 minutes.
Study NCT06538766 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training with a visual external focus of attention
Description: A 4 weeks strength training program of seated calf raises with progressive overload is carried out. A supervisor applies force specific visual external focus instruction in three sessions per week with at least 48h rest time. One session consists of 3 series until failure with 75%RM. Rest intervals between series are defined as 2 minutes.
Study NCT05302687 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: This project aims to evaluate differences in general women's health of women on probiotic and placebo via the use of questionnaire and evaluate differences in immunity of women on probiotic and placebo via blood immunity profiling. To evaluate differences in gut microbiota profiles of women on probiotic and placebo via blood fecal microbiota profiling.
Study NCT05302687 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: This project aims to evaluate differences in general women's health of women on probiotic and placebo via the use of questionnaire and evaluate differences in immunity of women on probiotic and placebo via blood immunity profiling. To evaluate differences in gut microbiota profiles of women on probiotic and placebo via blood fecal microbiota profiling.
Study NCT05215366 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: copeptin biomarker in children with febrile seizures
Description: biomarkers increase in children with febrile seizures
Study NCT05275569 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: True acupuncture + standard antiemetic treatment
Description: Participants will receive electroacupuncture once daily from day 1 to day 4. The acupuncturists will insert needles into the acupoints and manipulate the needles untilde qisensation is achieved and reported by the participants. Electrical stimulation will be delivered for 30 minutes at alternating frequencies of 2/10Hz. They will receive fosaprepitant 150 mg intravenous IV + palonosetron 0.25 mg IV + dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post chemotherapy.
Study NCT05275569 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham acupuncture + standard antiemetic treatment
Description: The sham acupuncture comprised a core standardized prescription of minimally invasive, shallow needle insertion using thin and short needles at body locations not recognized as true acupuncture points and are deemed to not belong to traditional Chinese meridians and have no therapeutic value. Participants will receive minimal acupuncture treatment without electrical stimulation at the same time as the intervention group.Care was taken to avoid de qi sensation. They will receive fosaprepitant 150 mg intravenous IV + palonosetron 0.25 mg IV + dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post-chemotherapy(the antiemetic drugs are the same as the true acupuncture group).
Study NCT04303000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid Overdose Education with Naloxone Distribution
Description: Online audiovisual training focused on recognizing the signs of an opioid overdose and administering naloxone. Participants are provided with a naloxone kit.
Study NCT04303000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid Overdose Education
Description: Online audiovisual training focused on recognizing the signs of an opioid overdose and administering naloxone. Participants are provided with information on where they can obtain a naloxone kit.
Study NCT04722185 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Veriton SPECT/CT
Description: The Veriton system represents an FDA approved (510k cleared) new generation of SPECT/CT systems. It consists of 12 small gamma cameras arrayed in a circle around the patient, and is coupled to a 64-slice CT system.
Study NCT05574179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine injection
Description: Inj precedex 200mcg in 1ml given in stat doses
Study NCT05574179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Inj.midazolam 5mg/5ml given in stat doses
Study NCT06312787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-118
Description: Tablets and Suspension for Oral Administration
Study NCT04909528 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-level tragus stimulation
Description: Frequency: 20Hz; Pulse width: 0.2 ms; Current is based on the following: Determine the perception threshold (feeling tingling) at the time of baseline information assessment. Because of sensory adaptation, ask the patient 5 minutes later to increase the current by 1-5 mA. Try to find the current level below the discomfort level and above the perception threshold; Stimulation spot: ear tragus; Stimulation time: 30 min in the morning (from 6:00 a.m. to 9:00 a.m.) and 30 min in the evening (from 20:00 p.m. to 23:00 p.m.)
Study NCT04909528 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Frequency: 20 Hz; Pulse width: 0.2 ms; Current is based on the following: Determine the perception threshold (feeling tingling) at the time of baseline information assessment. Because of sensory adaptation, ask the patient 5 minutes later to increase the current by 1-5 mA. Try to find the current level below the discomfort level and above the perception threshold; Stimulate spot: ear lobe. Stimulation time: 30 min in the morning (from 6:00 a.m. to 9:00 a.m.) and 30 min in the evening (from 20:00 p.m. to 23:00 p.m.)
Study NCT06349967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel Combined With Cadonilimab (AK104)
Description: Nab-paclitaxel 100mg/m2 ivgtt d1, d8, d15, q28d; Cadonilimab (AK104) 6mg/kg ivgtt d1, d15, q28d;
Study NCT05510960 — intervention group
Intervention type: OTHER
Intervention: Video game & Robotic surgery simulator success
Description: A questionnaire was administered to all participants, asking about their demographic information, surgical experience, hobbies, and previous video game playing experiences.~After the questionnaire, the participants were asked to play the Temple Run (Imangi Studios, NC, USA) and Piano Tiles 2™ mobile games for one month. At the end of the period, with the da Vinci® Skills Simulator™ for one hour, all participants performed four different robotic surgery simulator tasks (Camera Targeting 1, Energy Switching 1, Ring \& Rail 2, Vertical Defect Suturing) that require the ability to apply basic robotic surgery rules and measure surgical skills.
Study NCT05333159 — intervention group
Intervention type: DRUG
Intervention: SGLT2 inhibitor
Description: dapagliflozin 10mg once daily dose canagliflozin100mg once daily dose empagliflozin 0mg once daily dose
Study NCT05672433 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule without cafestol twice daily
Study NCT05672433 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cafestol
Description: Capsule with 6 mg cafestol twice daily
Study NCT06012097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac gel
Description: using diclofenac as a comparator
Study NCT06012097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatherapy gel
Description: using Aromatherapy gel as an experimetnal treatment
Study NCT05050760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab 200mg IV D1，Q3W,and preoperative therapy with three cycles.
Study NCT05050760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCF
Description: DCF:Oxaliplatin (85mg/ m\^2, IV D1,Q3W.Docetaxel: 60 mg/m\^2 intravenous infusion for 60 minutes, D1,Q3W.Tegafur:BSA\<1.25\^2,40 mg/time,1.25\^2\<BSA\<1.5\^2,50 mg/time,BID ,after breakfast and dinner, continuous administration for 14 days, rest for 7 days, as a treatment cycle;Repeat every 3 weeks
Study NCT04940234 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to a Photo
Description: We plan to recruit subjects and randomly assign them to one of four treatments. In each treatment arm, the subject will view a photo of a man. We experimentally vary treatment along two dimensions: whether the man is wearing expert vs. layperson attire and whether the man is white vs. black. We will survey participants' beliefs about the actors' educational attainment and perceived quality as measured by subjects' willingness to accept medical advice for non-urgent health issues or participate in a clinical trial being led by the individual in the photo.
Study NCT05361837 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single level serratus anterior plane block
Description: Serratus anterior plane block with local anesthetics at the third rib
Study NCT05361837 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single level serratus anterior plane block with dexmedetomidine
Description: Serratus anterior plane block with local anesthetics and dexmedetomidine at the third rib
Study NCT05361837 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilevel serratus anterior plane block
Description: Serratus anterior plane block with local anesthetics at the third and fifth rib
Study NCT04746924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab is a monoclonal antibody formulated for intravenous injection.
Study NCT04746924 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tislelizumab
Description: Tislelizumab is a monoclonal antibody formulated for intravenous injection.
Study NCT04746924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ociperlimab
Description: Ociperlimab is a monoclonal antibody formulated for intravenous injection.
Study NCT04746924 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab is a monoclonal antibody formulated for intravenous injection.
Study NCT04711096 — intervention group
Intervention type: PROCEDURE
Intervention: Ultrasound-guided transversus abdominis plane (TAP) block 0.25% bupivacaine.
Description: After preparing the skin with antiseptic solution, a linear high frequency ultrasound probe will be placed abdominal wall between the iliac crest and the costal margin. A Spinal needle 22g attached with flexible tubing to a syringe filled with saline will be used to perform the block then introduced through the skin anteriorly in the plane between the internal oblique and transversus abdominis muscles with its tip lying in the mid axillary line. To assist with identifying these structures, The final position of the probe will to be no further anterior than the anterior axillary line. If satisfactory views are not obtained, the TAP block will not be performed. Hydro dissection with saline (2-5 ml) will be used to separate the fascial layers. After aspiration to exclude inadvertent vascular puncture, 20 ml of the 0.25% bupivacaine will be injected . TAP block will be performed in a similar fashion on the opposite side.
Study NCT05361837 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilevel serratus anterior plane block with dexmedetomidine
Description: Serratus anterior plane block with local anesthetics and dexmedetomidine at the third and fifth rib
Study NCT05711368 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Distress tolerance training
Description: It consisted of seven sessions. A 90-minute session will be conducted twice a week for four weeks. The first introductory session will be concerned with helping the student learn how to engage in distress tolerance training and define goals of distress tolerance. At the end of the 1st session, a written plan for every session (time, duration and setting) will be scheduled individually with each student.The next six training sessions will cover three core skills which comprised three sets: Crisis Survival Skills, the skills of Reality Acceptance; and the Skills When the Crisis Is Addiction. The distress tolerance training methods will include individualized interactions, demonstration, and rehearsal, psychoeducation, practice exercises and homework assignments. Follow up between sessions will done using telephone calling and messaging in order to encourage performance homework assignments, and provide help and support when needed particularly at the time of stress. .
Study NCT04746924 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo infusions will consist of a sterile, normal saline solution.
Study NCT04746924 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusions will consist of a sterile, normal saline solution.
Study NCT05716672 — intervention group
Intervention type: DRUG
Intervention: Lazertinib
Description: Lazertinib 240mg(3tablets, 80mg/1tablet), once a day(QD), oral(PO), until disease progression or unacceptable toxicity
Study NCT05243849 — intervention group
Intervention type: DEVICE
Intervention: Optical Coherence Tomography Angiography
Description: Optical coherence tomography angiography (OCTA) is a novel non-invasive, non-dye and high-resolution imaging technique, allowing real-time quantitative evaluation of retinal vasculature and the structure of foveal avascular zone (FAZ).
Study NCT05479903 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: acupuncture
Description: Manual acupuncture or electro-acupuncture by experienced acupuncturists for patients
Study NCT05479903 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Manual acupuncture or electro-acupuncture by experienced acupuncturists for patients
Study NCT05479903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: computerized cognitive training system
Description: One-on-one cognitive training by an experienced cognitive therapist, combined with an existing computerized cognitive training system
Study NCT05479903 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: aerobic exercise
Description: Patients are trained by experienced physical therapists with the help of elastic bands and physical therapy devices
Study NCT05479903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: tranditional cognitive training
Description: One-on-one cognitive training with an experienced cognitive therapist, combined with traditional cognitive training methods (e.g., balls, cards, counting, daily conversation, etc.)
Study NCT05479903 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Treatment of underlying disease and stroke according to guidelines, as well as necessary care and rehabilitation
Study NCT05479903 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional treatment
Description: Treatment of underlying disease and stroke according to guidelines, as well as necessary care and rehabilitation
Study NCT05479903 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional treatment
Description: Treatment of underlying disease and stroke according to guidelines, as well as necessary care and rehabilitation
Study NCT05848661 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AUDISSEE
Description: AUDISSEE is a digital therapy designed specifically to improve the hearing in noise of presbycusis patients by offering a complete cognitive auditory training, with verbal and non-verbal stimuli. The therapy takes place over 10 weeks with 3 sessions of 20 minutes per week.
Study NCT05848661 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: AUDISSEE
Description: AUDISSEE is a digital therapy designed specifically to improve the hearing in noise of presbycusis patients by offering a complete cognitive auditory training, with verbal and non-verbal stimuli. The therapy takes place over 10 weeks with 3 sessions of 20 minutes per week.
Study NCT05848661 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The Placebo is a therapy designed within the same frame as the AUDISSEE therapy but with no auditory exercises, instead the patients are listening to audiobook. The therapy takes place over 10 weeks, with 3 sessions of 20 minutes per week.